Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Bleeding Problems

Bleeding Problems Abstract To the Editor. —Regarding the July and August Archives editorials by Gleckman and Gantz (1982;142:1267-1268) and Hochman et al (1982;142: 1440-1442), respectively, concerning bleeding problems attributable to the "third-generation cephalosporins and moxalactam disodium." It should come as no surprise that moxalactam has been associated with bleeding episodes as has cefamandole nafate and cefoperazone sodium. This has been well documented in the literature,1-10 and may well be attributable to the chemical structure of the respective compounds as well as affecting vitamin K—producing bacteria in the bowel. However, a search of the literature contains no references to bleeding associated with cefotaxime sodium. To date, at least, one may conclude that cefotaxime does not share the bleeding problems associated with the earlier mentioned compounds.The excellent plea for restraint in the use of these antibiotics is certainly shared by those of us who have had rather extensive experience in evaluating their potency References 1. Andrassy K, Koderisch J, Ritz E: Influence of cefotaxime (CTX), cefoperazone (CP) and lamoxactam (MOX) , in 22nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program Abstracts . Washington, DC, American Society for Microbiology, 1982, No. 523. 2. Bauman D, Holmes B, Pollock B, et al: Moxalactam in serious infections , in 20th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1980, No. 370. 3. Brown AE, Quesada O, Armstrong D: Empiric moxalactam therapy in febrile neutropenic patients with cancer on nephrotoxic chemotherapy , in 21st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1981, No. 318. 4. Fainstein V, Elting L, Bolivar R, et al: Moxalactam and ticarcillin or tobramycin for the treatment of neutropenic cancer patients , in 21st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1981, No. 317. 5. Holt RJ, Gorrochategui M, Perez C: Hypoprothrombinemia associated with moxalactam treatment of a septic sternoclavicular arthritis due to Citrobacter diversus. Drug Intell Clin Pharmacol 1981;15:780-783. 6. Lentnek L, Kidd L, Ryan R: Moxalactam (LY127935) in the treatment of serious bacterial infection , in 20th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1980, No. 369. 7. Mathisen G, Meyer RD, Thompson JM, et al: Clinical evaluation of moxalactam. Antimicrob Agents Chemother 1982;21:780-786.Crossref 8. Pakter R, Russell TR, Mielke CH, et al: Coagulopathy associated with the use of moxalactam. JAMA 1982;248:1100.Crossref 9. Schwigon CD, Barckow D: Efficacy and tolerance of cefotaxime (CTX), cefoperazone (CP) and lamoxactam (MOX) in intensive care patients , in 22nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1982, No. 819. 10. Srinivansan S, Francke EL, Neu HC: Use of moxalactam in the therapy of infections due to multi-resistant bacteria , in 20th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1980, No. 365. 11. Childs SJ, Wells WG, Mirelman S: Antibiotic prophylaxis for genitourinary surgery in community hospitals , in Eighth International Congress of Infectious and Parasitic Diseases . Stockholm, 1982, pp 166. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Internal Medicine American Medical Association

Loading next page...
 
/lp/american-medical-association/bleeding-problems-fD13nClRRe
Publisher
American Medical Association
Copyright
Copyright © 1983 American Medical Association. All Rights Reserved.
ISSN
0003-9926
eISSN
1538-3679
DOI
10.1001/archinte.1983.00350010195047
Publisher site
See Article on Publisher Site

Abstract

Abstract To the Editor. —Regarding the July and August Archives editorials by Gleckman and Gantz (1982;142:1267-1268) and Hochman et al (1982;142: 1440-1442), respectively, concerning bleeding problems attributable to the "third-generation cephalosporins and moxalactam disodium." It should come as no surprise that moxalactam has been associated with bleeding episodes as has cefamandole nafate and cefoperazone sodium. This has been well documented in the literature,1-10 and may well be attributable to the chemical structure of the respective compounds as well as affecting vitamin K—producing bacteria in the bowel. However, a search of the literature contains no references to bleeding associated with cefotaxime sodium. To date, at least, one may conclude that cefotaxime does not share the bleeding problems associated with the earlier mentioned compounds.The excellent plea for restraint in the use of these antibiotics is certainly shared by those of us who have had rather extensive experience in evaluating their potency References 1. Andrassy K, Koderisch J, Ritz E: Influence of cefotaxime (CTX), cefoperazone (CP) and lamoxactam (MOX) , in 22nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program Abstracts . Washington, DC, American Society for Microbiology, 1982, No. 523. 2. Bauman D, Holmes B, Pollock B, et al: Moxalactam in serious infections , in 20th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1980, No. 370. 3. Brown AE, Quesada O, Armstrong D: Empiric moxalactam therapy in febrile neutropenic patients with cancer on nephrotoxic chemotherapy , in 21st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1981, No. 318. 4. Fainstein V, Elting L, Bolivar R, et al: Moxalactam and ticarcillin or tobramycin for the treatment of neutropenic cancer patients , in 21st Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1981, No. 317. 5. Holt RJ, Gorrochategui M, Perez C: Hypoprothrombinemia associated with moxalactam treatment of a septic sternoclavicular arthritis due to Citrobacter diversus. Drug Intell Clin Pharmacol 1981;15:780-783. 6. Lentnek L, Kidd L, Ryan R: Moxalactam (LY127935) in the treatment of serious bacterial infection , in 20th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1980, No. 369. 7. Mathisen G, Meyer RD, Thompson JM, et al: Clinical evaluation of moxalactam. Antimicrob Agents Chemother 1982;21:780-786.Crossref 8. Pakter R, Russell TR, Mielke CH, et al: Coagulopathy associated with the use of moxalactam. JAMA 1982;248:1100.Crossref 9. Schwigon CD, Barckow D: Efficacy and tolerance of cefotaxime (CTX), cefoperazone (CP) and lamoxactam (MOX) in intensive care patients , in 22nd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1982, No. 819. 10. Srinivansan S, Francke EL, Neu HC: Use of moxalactam in the therapy of infections due to multi-resistant bacteria , in 20th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy Meeting-Program and Abstracts . Washington, DC, American Society for Microbiology, 1980, No. 365. 11. Childs SJ, Wells WG, Mirelman S: Antibiotic prophylaxis for genitourinary surgery in community hospitals , in Eighth International Congress of Infectious and Parasitic Diseases . Stockholm, 1982, pp 166.

Journal

Archives of Internal MedicineAmerican Medical Association

Published: Jan 1, 1983

References